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Abstract: The term retinitis pigmentosa (RP) indicates a heterogeneous group of genetic rare ocular diseases in which 
either rods or cones are prevalently damaged. RP represents the most common hereditary cause of blindness in people 
from 20 to 60 years old. In general, the different RP forms consist of progressive photo-receptorial neuro-degenerations, 
which are characterized by variable visual disabilities and considerable socio-sanitary burden. Sometimes, RP patients do 
not become visually impaired or legally blind until their 40-50 years of age and/or maintain a quite acceptable sight for all 
their life. Other individuals with RP become completely blind very early or in middle childhood. Although there is no 
treatment that can effectively cure RP, in some case-series the disease’s progression seems to be reducible by specific 
preventive approaches. In the most part of RP patients, the quality of vision can be considerably increased by means of 
nanometer-controlled filters. In the present review, the main aspects of the routine clinical and rehabilitative managements 
for RP patients are described, particularly focusing on the importance of specific referral Centers to practice a real 
multidisciplinary governance of these dramatic diseases. 
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INTRODUCTION 
  Inherited retinal dystrophies are a heterogeneous group of 
rare diseases affecting the posterior segment of the eye [1-6]. 
In the course of routine clinical practice, the different forms 
of retinitis pigmentosa (RP) are the most frequently 
diagnosed heredo-dystrophic pathologies of the retina, being 
neurodegenerative disorders of the tapetum, which 
represents a layer composed by perennial cells named retinal 
photoreceptors, i.e. rods and cones. The definition “tapeto-
retinal degeneration” has been firstly utilized by Leber in 
1916, describing an ocular disease that Donders in 1857 
defined as “retinitis pigmentosa”. Although this latter 
expression is not properly corrected, because the 
inflammation is not the main process in these eye disorders, 
retinitis pigmentosa is currently worldwide used. In the 
different ethnic groups, RP prevalence is variable reported in 
1 case for each 3000-5000 individuals [7-23], even if among 
particular populations the disease’s occurrence seems to be 
very higher [24, 25]. The different clinical RP-patterns are 
generally progressive and bilateral. Each of these phenotypes 
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is hereditable in line with all the typologies of the Mendelian 
inheritance. The various typologies of RP represent very 
complex eye diseases from both genotypic and phenotypic 
point of view. According to the clinical manifestations, two 
main groups of RP are schematically distinguishable: i. 
typical RP or rod-cone dystrophy (RCD) (about 80-90% of 
the total cases), in which the rods are predominantly 
damaged; ii. atypical RP or cone-rod dystrophy (CRD) 
(about 10-20% of the total cases), in which the cones are 
primarily injured. In the most part of patients with RCD or 
CRD (approximately 85% of cases), these ocular 
degenerative disorders are considerable as isolated diseases, 
i.e. non-syndromic RPs. However, many systemic disorders 
can be associated with various types of pigmentary 
retinopathies. In the large majority of patients affected by 
syndromic inherited retinal dystrophies, the clinical 
manifestation of their ocular involvement consists of a 
typical form of RP. These syndromic RPs approximately 
represent the 15% of the total cases suffering from tapeto-
retinal degeneration. Usher syndrome is the most frequent 
syndromic disorder, in which typical RP is associated with 
neuro-sensory deafness. About 14% of all RP cases are, in 
fact, Usher syndrome [4, 8, 13, 15, 16]. The deafness, 
normally congenital and stable, may be severe (type 1) or 
moderate (type 2); in other cases, it occurs during the first 
decade and progressively worsens (type 3). Clinical and Rehabilitative Management of Retinitis Pigmentosa  Current Genomics, 2011, Vol. 12, No. 4    251 
  As already mentioned, the RCD is characterized by a 
progressive neuro-degenerative damage mostly affecting 
rods, which are the retinal photoreceptors able to ensure both 
the nocturnal and the peripheral visions. In patients affected 
by early-stage RCD, a decreasing of the visual abilities in the 
dark (nyctalopia), a slight to moderate shrinking of the visual 
field and/or a remarkable dazzle sensation (photophobia) are 
often reported. This latter symptom is commonly detectable 
also in patients suffering from early-stage CRD. Moreover, 
because the cones are prevalently injured, these individuals 
usually complain about noticeable alterations of both 
quantity and quality of their central vision. Although many 
patients with late-stage RCD have peripheral or total 
blindness and numerous patients with late-stage CRD are 
centrally blind, the natural history of all tapeto-retinal 
degenerations is often unpredictable. In fact, the final visual 
prognosis of each RP patient can be dependent not only on 
genetic factors (such as different expressivity and/or 
penetrance of the causative disease-gene) [4-6, 26-28] but, 
sometimes, also on environmental factors (such as different 
levels of eye-exposure to harmful light radiations) [29-36]. 
  The aforementioned evidences, indicative of both inter-
familial genotypic multiplicity and intra-familial phenotypic 
variability of RP, are unavoidably related to a complex and 
customized management of each patient with either RCD or 
CRD, which involves peculiar clinico-genetic, psychological 
and rehabilitative aspects. 
MULTIDISCIPLINARY MANAGEMENT 
  In Caucasian ethnic groups, the total prevalence of RP is 
estimable in 32.2 cases per 100 000 persons [17]. This 
number is relatively low in comparison with the general 
population, but it is of critical importance especially 
considering the socio-sanitary characteristics of RP, together 
with its insidious and/or grave consequences. In fact, the 
different forms of RP often represent very disabling 
disorders, progressively more severe already during either 
school- or working-age, without any definite therapeutic 
strategy and, in many cases, associated with significant risk 
of hereditary transmission. Therefore, also to avoid an 
attitude of renunciation-care by several RP patients, the 
possibility of referring to a specialized Center, able to serve 
a catchment’s area inhabited by at least 1.5-2.5 millions of 
people, seems to be an appropriate option for the clinical 
governance of this rare eye disease. The presence of these 
referral RP services is essential to ensure that 
multidisciplinary approach in which different professionals 
work together trying to give feasible solutions to patient’s 
requests and/or effectual responses to those queries that a 
person with RP usually turns to the ophthalmologist: 
•  what is my visual capacities compared to those of 
healthy population? 
•  what kind of visual impairment should I expect and 
when? 
•  what is the better rational treatment for my disease? 
•  is it possible that other disorders (such as deafness, 
cataract, macular edema, ocular hypertension and/or 
glaucoma) come out? 
•  in these latter cases, how will you can treat me? 
•  what is the risk of RP transmission in my family? 
•  what socio-economic benefits and welfare rights can I 
get? 
•  can you do anything to improve my quality of vision 
and my quality of life? 
  The ideal clinical and rehabilitative management of 
patients with ascertained or suspected RP becomes 
practicable when the ophthalmologist is in a position to 
coordinate a work-team necessarily composed by other 
health-care professionals, who can be alternately or 
synergistically exploited. This multifaceted board should 
include: 
•  ophthalmologist, the coordinator of the work-team, 
who achieves the standardized phenotyping of each 
RP patient, assessing visual functions, planning the 
clinical follow-up, managing preventive, 
rehabilitative, medico-legal and/or epidemiological 
aspects, also acting in cooperation with patient’s 
association and/or with dedicated social networks; 
•  geneticist, who accomplishes the genetic counseling 
of RP patients or families, dealing the medical 
genetics, indicating the possibilities of molecular 
diagnosis, the perspectives of gene therapy, and the 
pharmacogenetic aspects; 
•  audiologist, a specialized health-care professional, 
who identifies, diagnoses, monitors and treats the 
disorders of the auditory and vestibular system 
portions of the ear; 
•  other specialized health-care professionals (just for 
example, nephrologist, dermatologist and neurologist) 
who define, diagnose, check and treat the various 
systemic disorders present in patients with syndromic 
RP forms; 
•  assistant in ophthalmology or orthoptist, a vision 
rehabilitator who periodically works, in case 
supported by an optometrist or optician, to optimize 
the practical training of each RP user of optical and/or 
electronic aids, improving eye movements (conjugate 
and/or tracking), fixation and its maintenance 
especially for the reading, PC and/or TV utilizations; 
•  typhologic and occupational therapist, who 
periodically works to optimize the practical training 
of each RP user of typhlo-tecnical aids, and to 
enhance the eye-hand collaboration, movement 
execution (skill, speed and/or precision), ability to 
handle and recognize objects; 
•  orientation and mobility trainer, responsible for 
education and training to make RP patient able to be 
autonomous in movements both in known and 
unknown locations; 
•  psychologist, who evaluates the psychological 
distress of an individual suffering from RP and/or 
his/her family, in case providing psychological 
support for a social re-integration of the patient 
(especially at school or at work) and also acting in 
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  In the next parts of the present review, the assisting 
approaches dedicated to patients with RP will be focused and 
discussed. 
CLINICAL GOVERNANCE 
  The main commitments of a referral Center specialized in 
the clinical governance of patients affected by RP can be 
summarized considering, at least, these essential activities: 
1.  correct diagnostic classification of each RP-case and 
early diagnosis, employing both conventional and 
multifocal electroretinograms, visual field examina-
tions, microperimetry, retinographies, retinal angio-
graphies, and optical coherence tomography (OCT); 
2.  certification of ocular rare disease, epidemiologic and 
medico-legal evaluations, information about 
opportunities and limitations of social-health system; 
3.  anamnestic study concerning the possible inheritance, 
genealogic trees and risk estimation of the heredo-
familial transmission; 
4.  appropriate and standardized phenotyping of each RP 
patient, accompanied by the collection of biological 
material aiming to DNA storage and extraction in 
view of the current chances of molecular diagnosis 
and/or the future prospects of broad spectrum DNA 
bio-molecular tests; 
5.  correct and realistic information about the current 
curative options for RP and their possible side effects; 
6.  specific and personalized protocols intended to 
optimize prevention, treatment and/or rehabilitation of 
every patients suffering from different forms of RP; 
7.  specific and personalized protocols intended to 
effectively manage the concomitant ocular disorders 
possibly correlated with RP, such as cataract and 
cystoid macular edema; 
8.  recommendations regarding lifestyle, such as not 
smoking, low-fat diet accompanied by abundant fruits 
and vegetables, and regular aerobic exercise; 
9.  general and specific recommendations concerning the 
assumption of drugs or herbal medications. 
  In particular, this latter point should be considered in the 
cases of ascertained or suspected iatrogenic interactions, and 
to possibly avoid in RP patients the following drugs: i. 
potential retino-toxic compounds, such as the cGMP-specific 
phosphodiesterase type-5 inhibitors (erectile dysfunction 
drugs), isotretinoin and other retinoids, anti-psychotic and 
anti-histaminic drugs containing phenothiazines, vigabatrin 
(an anti-epileptic drug), aminoquinoline (an anti-malarial 
drug), tamoxifen (an antagonist of the estrogen receptor), 
and high dosage of hydroxychloroquine (a drug used to treat 
or prevent malaria and, more frequently, to treat lupus and 
rheumatoid arthritis); ii. potential neuro-toxic compounds, 
such as ethambutol (an anti-mycobacterial drug), linezolid (a 
synthetic antibiotic), and amiodarone (an anti-arrhythmic 
agent); iii. drugs associated with potential risks of acute or 
intermittent angle closure glaucoma in susceptible 
individuals, such as tricyclic antidepressants and other agents 
with anti-cholinergic properties, serotonin-norepinephrine 
reuptake inhibitors and selective serotonin reuptake 
inhibitors (the most commonly used antidepressant drugs), 
adrenergic agents, and certain beta-2 adrenergic agonists 
[37-41]. In RP patients who need one or more of the 
aforementioned drugs, they should always be used under 
careful ophthalmologic supervision. 
CONVENTIONAL CURATIVE STRATEGIES 
  In the course of the routine clinical practice of a referral 
Centers dedicated to the clinical management of RP, the 
most frequent patient’s query concerns the therapeutic 
possibilities to block or reduce the progression of the 
degenerative retinal disorders. Although many curative 
attempts have been hitherto carried out, currently there is no 
definitive treatment for RP [42-44]. In fact, all these 
therapeutic approaches have not proved effective when 
subjected to critical review according to the criteria of the 
evidence-based medicine (EBM). For this reason, it is not 
possible to define any shared interventional guideline for the 
care of RP patients. However, the ophthalmologist of a 
referral RP Center can rationally recommend several 
strategies aimed to reduce the phenotypic severity of these 
neurodegenerative rare diseases of the ocular posterior 
segment. In general, these therapeutic possibilities, which 
may be labeled as “conventional treatments”, should not 
induce false expectations in patients and, thus, each of them 
must be proposed in a very rigorous manner, clearly 
detailing that: 
•  no significant chance of visual recuperation is 
envisage to patients; 
•  the most optimistic hope is represented by the 
stabilization or by a slowdown of the detrimental 
trend of the disease’s progression; 
•  both the disease’s progression and the final visual 
prognosis are mainly related to  several genetic 
factors, from which the individual expressivity of 
each disease-gene depends and against which nothing 
is actually effective at present. 
  In patients with a rare disease characterized by absence 
of EBM-supported treatments and high risk of severe 
disability, such as RP, the prescriptive attitude must be 
unavoidably based just on clinical case-series data and/or on 
experimental evidences. Starting from this deontological 
point of view, the decision-making therapy should be 
performed especially considering the risk/benefit ratio and, 
to minor extent, the cost/benefit ratio of each treatment. In 
particular, some curative strategies for RP, operating with 
synergistic mechanism of action, are proposable to 
temptatively downgrade the clinical worsening of this 
chronic eye disease in the long-term period: 
•  nanometer-controlled filtering lenses (light protection 
or anti-phototoxic medical device) [29-36]; 
•  supplementation with vitamin A palmitate (associated 
or not with the intake of docosahexaenoic acid or 
lutein) [45-52]; 
•  other nutritional supplements and off-label drugs, i.e. 
lutein supplementation [53, 54], nilvadipine [55-57], 
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Nanometer-Controlled Filtering Lenses 
  Blue light-filtering and ultraviolet light-filtering lenses 
reduce the phototoxic effects on retina. In particular, the 
sunlight contains a wide range of wavelengths (), part of 
which is harmful for the ocular structures, i.e. ultraviolet 
radiation ( = 200-400 nm), high-energy violet ( = 400-440 
nm) and blue ( = 440-500 nm) lights. The retinal photo-
toxicity of these radiations has been demonstrated in 
experimental models of RP. Moreover, several data from 
animal studies indicate that some pigmentary retinopathies 
are peculiarly susceptible to light damage [30-32, 34, 35]. 
The continuative use of one or more types of nanometer-
controlled filters can significantly reduce both ultraviolet and 
blue lights negative effects at the level of vitreoretinal tissues 
suffering from RP.  
  In the last years, these anti-phototoxic medical devices 
are available in numerous colorations, each of which is able 
to partially or totally block harmful wavelengths of the light. 
In particular, patients with RP are recommended to wear 
dark nanometer-controlled glasses outdoors. The 
employment of these amber spectacles should be useful to 
counteract the damages of ultraviolet rays and visible 
wavelengths up to about 511 nm or 527 nm. Ideally, to 
protect from the sunlight the best option is represented by the 
utilization of lenses blocking ultraviolet rays and radiations 
up to approximately 550 nm to filter blue-violet light. On the 
other hand, patients with RP can be also advised to wear 
clear nanometer-controlled spectacles both outdoors in 
cloudy days and indoors to diminish dazzle during PC/TV 
monitors use or under the illumination of halogen lamps. 
Although habitually yellow, orange or red filtering lenses are 
prescribed to minimize photophobia, because of less 
chromatic aberrations numerous RP patients experience a 
better tolerance and compliance by the use of filters also 
containing significant part of brown, mixed with the basic 
yellow, orange or red tints. 
  In addition, nanometer-controlled filters have an 
important role in rehabilitative management of RP patients 
[59, 60]. In fact, these devices optimize the quality of vision 
in the majority of individuals with RCD or CRD, increasing 
contrast sensitivity and decreasing glare. For the 
aforementioned reasons, many patients affected by RP 
decide to employ at least two pair of specific filtering glasses 
with different levels of light-absorption and light-protection 
basing on the ambient brightness conditions in which they 
are. Nanometer-controlled filters are available as polarized 
and non-polarized lenses and, of course, they can correct 
eventual refractive errors of the patient (myopia, 
hypermetropia and/or astigmatism). Finally, eyeshade and 
lateral protection can facilitate the protection against 
dazzling side-coming light rays. In theory, there is the 
possibility to utilize photo-chromic filters, even though they 
cannot be able to ensure the same degree of protection 
obtainable with the photo-static ones. 
  The patients with RP have usually need of continuative 
filters exploitation after the carrying out of cataract surgery, 
even if filtering intraocular lenses are implanted. Nanometer-
controlled sunglasses provide about 50% more 
ultraviolet/blue photo-protection than either violet or blue 
blocking intraocular lenses [61], nevertheless these specific 
surgical devices should be systematically used in all RP 
candidates to cataract extraction procedure. Optimal 
risk/benefit and cost/benefit ratios characterize the 
employment of nanometer-controlled filters, despite they are 
associated with alterations of colors perception. The 
comprehensive consideration of the above-described aspects 
makes desirable that Health Systems provide for the 
reimbursement of all the nanometer-controlled lenses 
required by each patient with early- or late-stage RP. 
Vitamin A Palmitate 
  The vitamin A supplementation may be notionally able to 
protect the photoreceptors by trophic and antioxidant effects. 
In the course of the last 15-18 years, Berson and co-workers 
have periodically reported that vitamin A palmitate in long-
term doses of 15,000 IU per day slowed down the photo-
receptorial functional damages studying several clusters of 
patients affected by heterogeneous forms of typical RP [45-
51]. At present, the ophthalmologists continue to debate the 
conclusions of these investigations, particularly questioning 
about “How strong is the evidence that nutritional 
supplements slow the progression of retinitis pigmentosa?” 
[52]. Although no definitive consensus has been reached on 
the usefulness of vitamin A, this treatment seems to be more 
efficient in cases of RP caused by mutations in RHO1 gene 
(see the study design of the clinical trial NCT00065455 in 
http://clinicaltrials.gov/). If a prolonged high-dosage 
supplementation of vitamin A palmitate is proposed, 
periodical blood test must be scheduled to monitor the levels 
of serum retinol (normal < 3.49 μmol/l, i.e. < 1 mg/l) and 
triglyceridemia (normal < 2.13 mmol/l, i.e. < 0.19 g/l), at 
least together with the check of the main liver enzymes 
(aspartate aminotransferase, alanine aminotransferase, and 
alkaline phosphatase) because the iatrogenic vitamin A 
accumulation prevalently occurs in this organ. In case of 
ascertained or suspected signs of hepato-toxicity the 
treatment must be discontinued. Moreover, considering that 
vitamin A should not be given to patients with RP caused by 
mutations in ABCA4 gene, specific genotypic analyses 
might be temptatively indicated before starting this 
supplementation to better define exclusion criteria [4, 44, 
62]. Likewise, starting from a phenotypic point of view, also 
the presence of hepatic disorders, potentially linked to 
excessive risk of drug-toxicity, should be considered to rule 
out some RP patients from treatment with high-dosage 
vitamin A. 
  In a subsequent study, Berson and co-workers have 
verified the effect of docosahexaenoic acid supplementation 
at 1200 mg/day in addition to vitamin A, indicating that the 
pathologic course of RP was downgraded by 
docosahexaenoic acid, but this positive outcome did not 
persist in the long-term period. Moreover, RP patients taking 
vitamin A palmitate, but not docosahexaenoic acid, benefited 
from an omega-3 rich diet (equivalent to eating salmon, tuna, 
mackerel, herring and/or sardines, once to two times a week) 
[49, 50]. Recently, the same group of researchers has 
conducted a 4-year clinical trial on RP patients taking 
vitamin A randomized to either placebo or lutein (12 
mg/day) regimen, concluding that this latter combined 
treatment is able to better counteract the visual field decline 
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  Without identification of the RP disease-gene, as well as 
without preliminary tests aimed to diagnose eventual 
hepatopathies, the risk/benefit ratio of high-dosage 
supplementation of vitamin A palmitate is not exactly 
definable. Hence, this therapeutic strategy should be utilized 
under a careful supervision of: i. visual functions (to 
promptly identify unexpected and/or potentially iatrogenic 
retinal deteriorations); ii. possible systemic side effects. 
Nutritional Supplements and Off-Label Drugs 
  Other therapeutic approaches should be considered 
during the personalized clinical management of each RP 
patient, in particular: 
•  supplementation with lutein, a xanthophyll repre-
senting one of numerous naturally-occurring carote-
noids, which, at 12 mg/day or more, may increase its 
physiologic effects in keeping the eyes safe from both 
oxidative stress and high-energy photons of blue light 
[53, 54]; 
•  nilvadipine, a calcium-channel blocker drug marketed 
for the treatment of high blood pressure and also for 
cerebral vascular disorders, which, at 4 mg/day, 
seems to be able to retard progression of central 
visual field defects in RP patients hypothetically 
through its neuroprotective anti-amyloid actions [55-
57]; 
•  exclusively in patients with fundus albipunctatus, a 
quite benign form of inherited RCD caused by a 
mutation in the gene encoding 11-cis-retinol 
dehydrogenase and mainly characterized by 
congenital stationary night blindness, the oral 
treatment with 9-cis-beta-carotene has been recently 
reported to recover the photo-receptorial changes 
secondary to this retinal dystrophy – the same therapy 
might be evaluated in other types of human RP with 
similar gene-related pathogenetic mechanisms [58]. 
  Considering the favorable safety profile of all the above-
mentioned medical therapies, both their risk/benefit and 
cost/benefit ratios appear to be acceptable. Similarly, also 
rasagiline, a selective inhibitor of monoamine oxidase type B 
utilized as anti-Parkinson drug, may be prescribed, even if its 
anti-apoptotic action has been documented just in animal 
model of RP [63]. 
  Finally, it could be eventually advisable the intake of 
various and/or combined nutritional supplements that 
potentially act as anti-oxidants, immuno-modulators, 
microcirculation adjuvants and/or photo-protectors. 
Although no supporting controlled datum exists, they 
notionally benefit the retina in which there can be a very 
high level of free radicals, as it happens in RP patients. 
INTERVENTIONAL STRATEGIES  FOR OCULAR 
COMPLICATIONS 
  In the course of the clinical practice of a referral Center 
for RP patients, it is necessary to carry out the most 
appropriate diagnostic and therapeutic approaches for the 
management of some specific eye disorders associated with 
RP. Particularly, the most frequent complications are 
cataract and macular edema. 
Cataract 
  In the majority of patients affected by RP, the typical 
form of crystalline lens opacity is represented by a posterior 
central sub-capsular cataract with a clear nucleus, which is 
variably present at early or mid stage of the disease’s 
evolution. Although this cataract is not widespread, its 
central location can partially blur the central and peri-central 
vision. However, the surgical procedure (i.e. 
phacoemulsification with implantation of intraocular lens) is 
not recommendable at initial cataract stages, especially for 
the risk to generate or upgrade photophobia. Once RP patient 
was correctly informed on the risk/benefit ratio of cataract 
surgery in his/her specific case, as well as considering the 
physiologic photo-protection related to the presence of 
crystalline lens, this wait-attitude appears to be rational and, 
habitually, very appreciated by patients. When the surgical 
procedure becomes necessary (usually at least after the 
development of a moderate senile cataract component), it 
should be proposed with special attention to: i. detailed 
information to patient (both positive and negative aspects); 
ii. opportunity to plan the employment of filtering 
intraocular lens [64, 65]; iii. scheduling specific diagnostic 
investigations before and after surgical procedure (i.e. optical 
coherence tomography of the macular area) [66]; iv. option 
to prescribe pre- and post-operative regimens to reduce the 
risk of occurrence or aggravation of post-surgical cystoid 
macular edema (topical and/or oral non-steroidal anti-
inflammatory drugs, eventually together with topical and/or 
oral carbonic anhydrase inhibitors) [67-70]. 
Macular Edema 
  In patients suffering from RP, macular edema frequently 
occurs, causing a variable decrease in the visual acuity 
and/or contrast sensitivity. It is typically characterized by the 
presence of cystoid intra-retinal alterations, and its 
pathogenesis is mainly related to the degenerative changes 
affecting the vitreoretinal structures of the posterior ocular 
segment. The cystoid macular edema occurring in RP 
patients may be also caused by tractional changes in the 
vitreoretinal limiting membrane [71], as well as by 
inflammatory conditions and/or events (such as eventual 
post-surgical disorders). Although the cystoid macular 
edema in RP patients is most often chronic, several 
pathologic forms may be successfully treated with carbonic 
anhydrase inhibitors such as acetazolamide sodium at a daily 
dose of 500 mg or less [72-74]. The continuative utilization 
of this drug should be performed under strict medical 
supervision. In some case-series, also the topical 
administration of dorzolamide is efficient in downgrading 
cystoid macular edema [75-78]. Finally, either intravitreal or 
sub-Tenon posterior triamcinolone acetonide injection could 
be employed for select cases of cystoid macular edema in RP 
patients but its efficacy seems to be limited over time [79-
83]. 
CRITICAL REVIEW OF OTHER INTERVENTIONAL 
ATTEMPTS 
  In the last one-hundred years, more than fifty very 
different treatments for RP have been proposed and 
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effective according to the EBM criteria. These approaches 
are briefly, even if incompletely, condensable as follows: i. 
autologus or heterologus retro-choroidal grafts; ii. 
intravitreal, peribulbar, retrobulbar and/or subconjunctival 
injections with various drugs, herbal medications, vitamins, 
enzymes, antioxidants, mineral salts, L-DOPA, retinal lipoid 
extracts, vasodilators, platelet inhibitors, carbonic anhydrase 
inhibitors, immuno-modulatory agents; iii. laser therapy, 
magnetic therapy, ultrasound therapy, acupuncture, electrical 
stimulation, neuro-sensorial photo-stimulation through 
photoreceptor biofeedback and so on. Considering both 
risk/benefit and cost/benefit ratios, all the above-listed 
therapeutic attempts are currently not recommended by the 
Health Systems of United States, Canada, Europe and 
Australia, as well as in other many Nations. In particular, an 
interventional strategy had become quite common among 
patients with RP during the last three decades, i.e. the so-
called “Cuban therapy”. This intervention comprises: i. 
surgical approach, wrongly labeled as “revitalizing”, which 
consists in the insertion of autologus orbital adipo-vascular 
tissue into a 180-degree sclerochoroidal pocket at the 
temporal side of the eyeball; ii. periodical sessions of 
intravenous ozone-therapy; iii. periodical cranium-orbital 
electro-stimulating treatments; iv. oral administration of anti-
platelets, antioxidants and immuno-modulators. Performing 
this approach and comparing it with the natural history of RP 
in 195 patients, Peláez and co-workers have reported rather 
encouraging results, especially in the early stages of the 
disease [84-86]. However, these data have been never 
validated and, at present, the “Cuban therapy” is not 
performed and not advisable [87-90], as well as other similar 
surgical strategies: i. the so-called “Russian therapy” 
consisting in the retro-choroidal grafts of powdered extracts 
of heterologus biological material (named “alloplant”) [91, 
92]; ii. the so-called “Cuban-modified therapy” consisting in 
the insertion of autologus orbital adipo-vascular tissue into a 
20-degree temporal sclerochoroidal pocket. 
  Finally, another interventional strategy, characterized by 
both far-and-wide debated mechanism of action and 
criticizable risk/benefit ratio, is still infrequently applied to 
RP patients, i.e. the hyperbaric oxygen therapy. In few series 
of patients with RP, this long-term treatment has been 
supposedly able to stabilize the disease’s changes measured 
with perimetric and/or electroretinographic exams [93, 94]. 
These outcomes have indicated that hyper-oxygenated 
regimen could be related to a better chance of slowing RP 
progression in respect of the high-doses treatment with 
vitamin A [94] but, at present, it is generally not 
recommended, as well as any other hyper-oxygenation 
tissular strategy, such as intravenous ozone therapy. In fact, 
an increase of hyper-oxidant risks has been postulated, 
mainly owing to the release of oxygen free radicals and to 
the aberrant overloading of catabolic products harmful to 
retina [95-97]. Both these mechanisms are potentially related 
to a final worsening of the visual prognosis in RP patients. 
REHABILITATIVE MANAGEMENT 
  Several patients with RP gradually experienced different 
typologies of important visual impairment and disability. 
Specific rehabilitation trainings are usually very helpful and, 
thus, they should be timely programmed. In the severe cases 
of either RP/RCD (prevalently associated with peripheral 
visual loss) or RP/CRD (prevalently associated with central 
visual loss), low-vision aids are frequently useful: hand-held 
or stand magnifiers, half-eye base-in prism lenses, 
telescopes, hand-held or stand electronic devices and other 
equipments (above all in RP/CRD cases), possibly together 
with orientation and mobility training (above all in RP/RCD 
cases) [59, 60, 98-102]. Although the reading performance 
of most patients with RP/RCD is impaired not only for 
alterations of contrast sensitivity and visual acuity but also 
for visual field constriction [103], the utilization of 
electronic vision enhancement systems may be advisable in 
several individuals, especially the young ones. The 
completion of visual rehabilitation can improve daily-life 
activities and a high level of patient’s satisfaction is often 
reported. In all individuals affected by RP, a particular 
emphasis should be put on nanometer-controlled filtering 
lenses, which are commonly able to minimize photophobia 
outstandingly increasing the quality of vision [59, 60, 98]. 
The rehabilitation processes are aimed to maintain patient’s 
independence at home and in the community; they involve 
an accurate assessment of the sight functions, followed by 
peculiar exercises with optical and/or electronic vision aids. 
  In the most part of RP patients suffering from low-vision 
or blindness, the rehabilitative management is complex 
especially because the person to be rehabilitated is in school 
or working age. In fact, these individuals are often severely 
disabled or legally blind by the end of the second, third or 
fourth decade of life. For that reason, it is important that 
their education focuses on an adapted professional 
occupation (telephone operator, teaching, computer based 
activities, physiotherapist). Moreover, psychological support 
is often necessary in the course of several landmarks 
regarding a neurodegenerative inherited disease, such as RP: 
announcement, information about the procreative risks, 
occurrence of moving difficulties, loss of reading and/or 
other visual troubles. This care can be provided by either 
professionals or supportive patients associations. The 
disabled persons with RP should be also oriented to 
Institutions that help them to rehabilitate (short- and 
medium-stay stages) and/or to obtain new professional skills. 
Independently from the causative tapeto-retinal disorder, 
important benefits are often obtainable in RP patients 
suffering from low-vision or blindness, respectively, by 
means of rehabilitative or typhlo-tecnical devices, enabling 
them to take part in several occupational/social activities and 
to greatly improve their quality of life. The final aim is to 
optimize the remaining visual capacities or the other 
perceptive capacities, so that an individual can, at least 
partially, continue to do routine tasks and job activities, 
reaching meaningful personal aspirations. 
CONCLUSION 
  At present, the clinical management of the different RP 
forms should be carried out optimizing that multidisciplinary 
approach essential to meet all the complex care needs of 
each patient. Ideally, this optimization is achievable through 
the continuous activities of a consolidated work-team, 
coordinated by an ophthalmologist responsible of specific 
referral Centers for RP. In a shared view of collaborative 
network, each RP Center should be able to agree with the 256    Current Genomics, 2011, Vol. 12, No. 4  Parmeggiani et al. 
others about the main clinical guidelines standardizing, at 
least, a comprehensive phenotyping protocol, a minimal 
therapeutic planning and some psycho-rehabilitative 
approaches. Therefore, both the chief ophthalmologist and 
the other professional employees of a specific health-care 
Center for an ocular rare disease, such as RP, should be 
expressly trained to handle the multifaceted aspects of each 
case. Despite various curative strategies are available, or 
becoming potentially available, to restore or stabilize vision 
loss caused by RPs, currently the most part of these therapies 
do not be definitely validated in humans. Comprehensively 
taking into account several scientific, medical, deontological 
and psychological aspects, the lack of any effective treatment 
for RP makes difficult a categorical choice between different 
prescriptive attitudes toward this very severe pathology; in 
fact, the application of either EBM or complementary and 
alternative medicine criteria [104] may be inadequate in the 
context of RP decision-making. The emotional impact to 
researchers, clinicians, patients, and families from the recent 
results in molecular diagnosis, gene therapy and other 
pioneering treatments is very evident [6, 105-130]. Certainly, 
the above-cited considerations must not lead to excessive 
patient’s expectations and, above all, must not divert 
attention from that should be recommended during the 
routine clinical practice. However, several realistic chances 
of bridging the gap from RP lab to RP patients are getting 
closer. In the near future, an extensive application of these 
opportunities appears to be feasible only if a reinforced 
educational attitude will increase the number of 
ophthalmologists and geneticists able to work together. 
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